WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H532002
CAS#: 1354037-26-5
Description: KH-CB19 is a potent and selective inhibitor of CDC2-like kinase (CLK) 1 and 4. KH-CB19 suppresses serine/arginine-rich protein phosphorylation by CLKs under proinflammatory conditions.
Hodoodo Cat#: H532002
Name: KH-CB19
CAS#: 1354037-26-5
Chemical Formula: C15H13Cl2N3O2
Exact Mass: 337.04
Molecular Weight: 338.190
Elemental Analysis: C, 53.27; H, 3.87; Cl, 20.96; N, 12.43; O, 9.46
Synonym: KH-CB19; KH CB19; KHCB19.
IUPAC/Chemical Name: ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methylindole-2-carboxylate
InChi Key: CXJCGSPAPOTTSF-VURMDHGXSA-N
InChi Code: InChI=1S/C15H13Cl2N3O2/c1-3-22-15(21)14-11(8(6-18)7-19)9-4-5-10(16)12(17)13(9)20(14)2/h4-6H,3,18H2,1-2H3/b8-6-
SMILES Code: O=C(C(N1C)=C(/C(C#N)=C\N)C2=C1C(Cl)=C(Cl)C=C2)OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 338.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets. 2014 May;15(5):539-50. Review. PubMed PMID: 24568585.
2: Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. doi: 10.1016/j.chembiol.2010.11.009. PubMed PMID: 21276940; PubMed Central PMCID: PMC3145970.
3: Grant SK, Lunney EA. Kinase inhibition that hinges on halogen bonds. Chem Biol. 2011 Jan 28;18(1):3-4. doi: 10.1016/j.chembiol.2011.01.003. PubMed PMID: 21276931.